{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:53:22Z","timestamp":1768092802649,"version":"3.49.0"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AR019616"],"award-info":[{"award-number":["RO1AR019616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.trsl.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:13:47Z","timestamp":1610237627000},"page":"139-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition"],"prefix":"10.1016","volume":"231","author":[{"given":"Fabian A.","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsoles","family":"Piera-Velazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0002","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.trsl.2021.01.001_bib0003","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.01.001_bib0006","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","article-title":"Unraveling SSc pathophysiology; the myofibroblast","volume":"9","author":"van Caam","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/BOR.0000000000000543","article-title":"Insights into myofibroblasts and their activation in scleroderma: opportunities for therapy?","volume":"30","author":"Gyftaki-Venieri","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","article-title":"Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis","volume":"209","author":"Korman","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0010","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/art.23634","article-title":"Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis","volume":"58","author":"Rosenbloom","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2021.01.001_bib0011","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/ard.2009.120196","article-title":"Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies","volume":"69","author":"Distler","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0012","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2010.04.026","article-title":"Tyrosine kinases in inflammatory dermatologic disease","volume":"65","author":"Paniagua","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0013","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","article-title":"Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease","volume":"1832","author":"Beyer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2021.01.001_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2006.06.001","article-title":"Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis","volume":"5","author":"Verrecchia","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2021.01.001_bib0016","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2741\/s22","article-title":"Transforming growth factor-beta in systemic sclerosis (scleroderma)","volume":"1","author":"Varga","year":"2009","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0017","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta\u2014at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/370341a0","article-title":"Mechanism of activation of the TGF-beta receptor","volume":"370","author":"Wrana","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0019","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-beta signal transduction","volume":"67","author":"Massague","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0021","doi-asserted-by":"crossref","first-page":"27846","DOI":"10.1074\/jbc.M603721200","article-title":"Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures","volume":"281","author":"Wilkes","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0022","doi-asserted-by":"crossref","first-page":"F413","DOI":"10.1152\/ajprenal.00082.2003","article-title":"Smad3 and PKCdelta mediate TGF-beta1-induced collagen I expression in human mesangial cells","volume":"285","author":"Runyan","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0023","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-5793(98)00011-8","article-title":"Vascular types I and II transforming growth factor-beta receptor expression: differential dependency on tyrosine kinases during induction by TGF-beta","volume":"422","author":"Ward","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.trsl.2021.01.001_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(90)90801-K","article-title":"Signal transduction by receptors with tyrosine kinase activity","volume":"61","author":"Ullrich","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0027","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0028","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0029","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1183\/09031936.00149614","article-title":"The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis","volume":"45","author":"Grimminger","year":"2015","journal-title":"Eur Respir J"},{"issue":"Suppl 5","key":"10.1016\/j.trsl.2021.01.001_bib0030","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1093\/rheumatology\/ken276","article-title":"Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis","volume":"47","author":"Distler","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0031","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/BOR.0b013e32833f1105","article-title":"Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis","volume":"22","author":"Gordon","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0032","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/art.30545","article-title":"Tyrosine kinase inhibitor therapy for systemic sclerosis: quo vadis?","volume":"63","author":"Mendoza","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022061","article-title":"TGF-beta signaling from receptors to Smads","volume":"8","author":"Hata","year":"2016","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7113-8_1","article-title":"Human fibrotic diseases: current challenges in fibrosis research","volume":"1627","author":"Rosenbloom","year":"2017","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/emboj\/16.8.1970","article-title":"Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues","volume":"16","author":"Luo","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.trsl.2021.01.001_bib0036","doi-asserted-by":"crossref","first-page":"14850","DOI":"10.1074\/jbc.272.23.14850","article-title":"The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues","volume":"272","author":"Lawler","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0037","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0092-8674(92)90152-3","article-title":"Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine\/threonine kinase","volume":"68","author":"Lin","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0038","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/0008-5472.CAN-06-3851","article-title":"Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion","volume":"67","author":"Galliher","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0039","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jphp.12530","article-title":"Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response","volume":"68","author":"Bernard","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0014-4827(74)90484-4","article-title":"Platelets as a source of fibroblast growth-promoting activity","volume":"87","author":"Kohler","year":"1974","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0041","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1073\/pnas.71.4.1207","article-title":"A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro","volume":"71","author":"Ross","year":"1974","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.trsl.2021.01.001_bib0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(86)90733-6","article-title":"The biology of platelet-derived growth factor","volume":"46","author":"Ross","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0043","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of action and in vivo role of platelet-derived growth factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.trsl.2021.01.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1242\/dev.155879","article-title":"Tracing the destiny of mesenchymal stem cells from embryo to adult bone marrow and white adipose tissue via Pdgfralpha expression","volume":"145","author":"Miwa","year":"2018","journal-title":"Development"},{"key":"10.1016\/j.trsl.2021.01.001_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jchemneu.2018.06.001","article-title":"Markers for human brain pericytes and smooth muscle cells","volume":"92","author":"Smyth","year":"2018","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.trsl.2021.01.001_bib0046","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.trsl.2021.01.001_bib0047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1098\/rstb.1990.0051","article-title":"Platelet-derived growth factor and its role in health and disease","volume":"327","author":"Ross","year":"1990","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0048","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.me.38.020187.000443","article-title":"Platelet-derived growth factor","volume":"38","author":"Ross","year":"1987","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0049","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1074\/jbc.M413806200","article-title":"Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts","volume":"280","author":"Bromann","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0050","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1073\/pnas.90.16.7696","article-title":"The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells","volume":"90","author":"Twamley-Stein","year":"1993","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.trsl.2021.01.001_bib0051","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (review)","volume":"16","author":"Ying","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0052","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mam.2017.11.008","article-title":"PDGF in organ fibrosis","volume":"62","author":"Klinkhammer","year":"2018","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0053","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Suppl 5","key":"10.1016\/j.trsl.2021.01.001_bib0054","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","article-title":"Role of PDGF in fibrotic diseases and systemic sclerosis","volume":"47","author":"Trojanowska","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"Gay","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0056","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.1780331011","article-title":"Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis","volume":"33","author":"Klareskog","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0057","first-page":"1876","article-title":"Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma","volume":"22","author":"Ludwicka","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0058","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13075-015-0575-8","article-title":"Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis","volume":"17","author":"Clark","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0059","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0923-1811(98)00027-9","article-title":"Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma","volume":"18","author":"Zheng","year":"1998","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0060","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.imbio.2012.10.004","article-title":"Platelet derived growth factor-CC secreted by M2 macrophages induces alpha-smooth muscle actin expression by dermal and gingival fibroblasts","volume":"218","author":"Glim","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.trsl.2021.01.001_bib0061","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1096\/fasebj.11.13.9367346","article-title":"Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation","volume":"11","author":"Myllarniemi","year":"1997","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2021.01.001_bib0062","first-page":"75","article-title":"Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro","volume":"8","author":"Svegliati","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0063","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","article-title":"A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate","volume":"28","author":"Bhattacharyya","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.trsl.2021.01.001_bib0064","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/art.23698","article-title":"Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate","volume":"58","author":"Pannu","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0065","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.70.9.2702","article-title":"Pituitary extracts and steroid hormones in the control of 3T3 cell growth","volume":"70","author":"Armelin","year":"1973","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.01.001_bib0066","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/268528a0","article-title":"Factors from 3T3 cells stimulate proliferation of cultured vascular endothelial cells","volume":"268","author":"Birdwell","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0067","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/249123a0","article-title":"Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth","volume":"249","author":"Gospodarowicz","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0068","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1083\/jcb.66.2.451","article-title":"Mitogenic effect of fibroblast growth factor on early passage cultures of human and murine fibroblasts","volume":"66","author":"Gospodarowicz","year":"1975","journal-title":"J Cell Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0069","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ydbio.2005.09.011","article-title":"Functions and regulations of fibroblast growth factor signaling during embryonic development","volume":"287","author":"Thisse","year":"2005","journal-title":"Dev Biol"},{"issue":"Suppl 5","key":"10.1016\/j.trsl.2021.01.001_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jcp.1041330405","article-title":"Fibroblast growth factor: structural and biological properties","author":"Gospodarowicz","year":"1987","journal-title":"J Cell Physiol Suppl"},{"key":"10.1016\/j.trsl.2021.01.001_bib0071","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0955-2235(89)90012-4","article-title":"The fibroblast growth factor family: structural and biological properties","volume":"1","author":"Klagsbrun","year":"1989","journal-title":"Prog Growth Factor Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0072","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0073","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1677\/erc.0.0070165","article-title":"Fibroblast growth factors, their receptors and signaling","volume":"7","author":"Powers","year":"2000","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.trsl.2021.01.001_bib0074","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0075","doi-asserted-by":"crossref","first-page":"92S","DOI":"10.1038\/jid.1993.30","article-title":"Control of fibrosis in systemic scleroderma","volume":"100","author":"Mauch","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0076","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/path.4768","article-title":"Fibroblast growth factor-1 attenuates TGF-beta1-induced lung fibrosis","volume":"240","author":"Shimbori","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0077","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/path.5106","article-title":"Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation","volume":"246","author":"Koo","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0078","first-page":"90","article-title":"Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen alpha 2(I) gene expression in scleroderma and normal fibroblasts","volume":"24","author":"Ichiki","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0079","doi-asserted-by":"crossref","first-page":"16633","DOI":"10.1038\/s41598-018-34747-3","article-title":"Fibroblast growth factor-2, but not the adipose tissue-derived stromal cells secretome, inhibits TGF-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts","volume":"8","author":"Liguori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0080","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/ijms20184634","article-title":"FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis","volume":"20","author":"Bockmann","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0081","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00424-020-02363-8","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha)-dependent regulation of fibroblast growth factor 23 (FGF23)","volume":"472","author":"Ewendt","year":"2020","journal-title":"Pflug Arch"},{"key":"10.1016\/j.trsl.2021.01.001_bib0082","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1165\/rcmb.2004-0242OC","article-title":"Fibroblast growth factor-10 prevents asbestos-induced alveolar epithelial cell apoptosis by a mitogen-activated protein kinase-dependent mechanism","volume":"32","author":"Upadhyay","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0083","doi-asserted-by":"crossref","first-page":"37445","DOI":"10.1038\/srep37445","article-title":"Developmental reprogramming in mesenchymal stromal cells of human subjects with idiopathic pulmonary fibrosis","volume":"6","author":"Chanda","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0084","doi-asserted-by":"crossref","first-page":"L615","DOI":"10.1152\/ajplung.00185.2015","article-title":"FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro","volume":"310","author":"Joannes","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0085","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2021.01.001_bib0086","first-page":"209","article-title":"Vascular endothelial growth factor: basic biology and clinical implications","volume":"79","author":"Ferrara","year":"1997","journal-title":"EXS"},{"key":"10.1016\/j.trsl.2021.01.001_bib0087","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell."},{"key":"10.1016\/j.trsl.2021.01.001_bib0088","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.0000134644.89917.96","article-title":"Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis","volume":"95","author":"Distler","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0089","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms19051269","article-title":"VEGF (vascular endothelial growth factor) and fibrotic lung disease","volume":"19","author":"Barratt","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1164\/rccm.201603-0568OC","article-title":"Differential epression of VEGF-Axxx isoforms is critical for development of pulmonary fibrosis","volume":"196","author":"Barratt","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0091","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","article-title":"Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis","volume":"109","author":"Manetti","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0092","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1097-2765(00)80004-0","article-title":"An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors","volume":"1","author":"Shrivastava","year":"1997","journal-title":"Mol Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0093","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1097-2765(00)80003-9","article-title":"The discoidin domain receptor tyrosine kinases are activated by collagen","volume":"1","author":"Vogel","year":"1997","journal-title":"Mol Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0094","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.bbapap.2012.10.014","article-title":"Collagen recognition and transmembrane signalling by discoidin domain receptors","volume":"1834","author":"Carafoli","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2021.01.001_bib0095","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1074\/jbc.R112.444158","article-title":"Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling","volume":"288","author":"Fu","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0096","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-800180-6.00002-5","article-title":"Discoidin domain receptor functions in physiological and pathological conditions","volume":"310","author":"Leitinger","year":"2014","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0097","first-page":"1355","article-title":"Role of discoidin domain receptor 2 in wound healing","volume":"29","author":"Marquez","year":"2014","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0098","first-page":"386","article-title":"DDR1 and DDR2 in skin","volume":"12","author":"Cario","year":"2018","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.trsl.2021.01.001_bib0099","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000479119","article-title":"The role of discoidin domain receptor 1 in inflammation, fibrosis and renal disease","volume":"137","author":"Dorison","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.trsl.2021.01.001_bib0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.matbio.2013.12.002","article-title":"Discoidin domain receptors in disease","volume":"34","author":"Borza","year":"2014","journal-title":"Matrix Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0101","first-page":"348","article-title":"Mechanical signaling through the discoidin domain receptor 1 plays a central role in tissue fibrosis","volume":"12","author":"Coelho","year":"2018","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.trsl.2021.01.001_bib0102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/jid.2012.252","article-title":"Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts","volume":"133","author":"Makino","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.drudis.2014.09.025","article-title":"Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery","volume":"20","author":"Kothiwale","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.trsl.2021.01.001_bib0104","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-019-0825-x","article-title":"Ephrins and Eph receptor signaling in tissue repair and fibrosis","volume":"21","author":"Wu","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrm.2015.16","article-title":"Mechanisms of ephrin-Eph signalling in development, physiology and disease","volume":"17","author":"Kania","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0107","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/rheumatology\/keq448","article-title":"Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis","volume":"50","author":"Avouac","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trsl.2021.01.001_bib0108","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/nm.4419","article-title":"ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis","volume":"23","author":"Lagares","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0109","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.117.311045","article-title":"EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-beta\/Smad3 signaling","volume":"121","author":"Su","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biocel.2018.10.006","article-title":"Therapeutic potential of targeting the Eph\/ephrin signaling complex","volume":"105","author":"Saha","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0111","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0092-8674(00)81812-7","article-title":"Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning","volume":"87","author":"Davis","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.01.001_bib0112","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1126\/science.286.5449.2511","article-title":"Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1","volume":"286","author":"Thurston","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.01.001_bib0113","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/01.ATV.0000140819.81839.0e","article-title":"Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements","volume":"24","author":"Hegen","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0114","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00296-012-2378-4","article-title":"Circulating angiopoietin and Tie-2 levels in systemic sclerosis","volume":"33","author":"Dunne","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.trsl.2021.01.001_bib0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-017-1304-2","article-title":"Tie2 as a novel key factor of microangiopathy in systemic sclerosis","volume":"19","author":"Moritz","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0116","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10408363.2013.874403","article-title":"Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells","volume":"51","author":"Gocek","year":"2014","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0117","doi-asserted-by":"crossref","first-page":"s595","DOI":"10.2741\/1106","article-title":"Non-receptor protein tyrosine kinases","volume":"8","author":"Tsygankov","year":"2003","journal-title":"Front Biosci"},{"key":"10.1016\/j.trsl.2021.01.001_bib0118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2443.1996.d01-234.x","article-title":"Vertebrate non-receptor protein-tyrosine kinase families","volume":"1","author":"Neet","year":"1996","journal-title":"Genes Cells"},{"key":"10.1016\/j.trsl.2021.01.001_bib0119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-018-0788-y","article-title":"Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products","volume":"17","author":"Siveen","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2021.01.001_bib0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-1-60761-500-2_28","article-title":"PDGF receptor and its antagonists: role in treatment of PAH","volume":"661","author":"Grimminger","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00403-014-1532-0","article-title":"Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts","volume":"307","author":"Karimizadeh","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0122","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.01.001_bib0124","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.01.001_bib0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7326\/0003-4819-152-3-201002020-00007","article-title":"Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies","volume":"152","author":"Rosenbloom","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0126","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2733fje","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2021.01.001_bib0128","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1152\/ajprenal.00320.2009","article-title":"Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis","volume":"298","author":"Wang","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1172\/JCI200112347","article-title":"Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts","volume":"108","author":"Jimenez","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.01.001_bib0130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/art.30284","article-title":"The c-Abl tyrosine kinase controls protein kinase Cdelta-induced Fli-1 phosphorylation in human dermal fibroblasts","volume":"63","author":"Bujor","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0131","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.27443","article-title":"MicroRNA-29, a key regulator of collagen expression in systemic sclerosis","volume":"62","author":"Maurer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2 Suppl 71","key":"10.1016\/j.trsl.2021.01.001_bib0132","first-page":"S86","article-title":"Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro","volume":"30","author":"Hinchcliff","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 113(4)","key":"10.1016\/j.trsl.2021.01.001_bib0133","first-page":"36","article-title":"Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts","volume":"36","author":"Piera-Velazquez","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0134","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/art.30317","article-title":"Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-mesenchymal transition in vitro","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0135","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1152\/physrev.00021.2018","article-title":"Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases","volume":"99","author":"Piera-Velazquez","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.trsl.2021.01.001_bib0136","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: rheostats of immune cell signaling","volume":"41","author":"Lowell","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbamcr.2005.03.004","article-title":"Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase","volume":"1745","author":"Catarzi","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2021.01.001_bib0138","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cells9030558","article-title":"Src inhibition attenuates liver fibrosis by preventing hepatic stellate cell activation and decreasing connetive tissue growth factor","volume":"9","author":"Seo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.trsl.2021.01.001_bib0139","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41419-020-2229-2","article-title":"Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo","volume":"11","author":"Du","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0140","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/jcp.22173","article-title":"Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts","volume":"224","author":"Zhang","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0141","doi-asserted-by":"crossref","first-page":"C1361","DOI":"10.1152\/ajpcell.00370.2006","article-title":"TGF-beta-regulated collagen type I accumulation: role of Src-based signals","volume":"292","author":"Mishra","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0142","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/annrheumdis-2018-213239","article-title":"Slit2\/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis","volume":"77","author":"Romano","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0143","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.01.001_bib0144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/1043-2760(94)90096-5","article-title":"Signaling by the cytokine receptor superfamily just another kinase story","volume":"5","author":"Ihle","year":"1994","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.trsl.2021.01.001_bib0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0146","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0147","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.trsl.2021.01.001_bib0148","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.01.001_bib0149","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S2213-2600(20)30001-1","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Rahimi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0151","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0152","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0960-894X(96)00601-4","article-title":"Potent and selective inhibitors of the Abl-phenylamino=pyrimidine (PAP) derivatives","volume":"7","author":"Zimmermann","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.trsl.2021.01.001_bib0153","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.01.001_bib0154","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.01.001_bib0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0156","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2021.01.001_bib0157","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V99.1.381","article-title":"Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis","volume":"99","author":"Beham-Schmid","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.01.001_bib0158","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1568026620666200124094949","article-title":"Phenylamino-pyrimidine (PAP) privileged structure: synthesis and medicinal applications","volume":"20","author":"Ferreira Pimentel","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.trsl.2021.01.001_bib0159","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/COC.0000000000000023","article-title":"Off-target effects of BCR-ABL and JAK2 inhibitors","volume":"39","author":"Green","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0160","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.40934","article-title":"Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response?","volume":"71","author":"Martyanov","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0161","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JEP.S26894","article-title":"Pharmacology and rationale for imatinib in the treatment of scleroderma","volume":"5","author":"Moinzadeh","year":"2013","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0162","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0163","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0164","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000111507","article-title":"The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study","volume":"216","author":"Soria","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.trsl.2021.01.001_bib0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/s10165-011-0472-1","article-title":"Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases","volume":"22","author":"Tamaki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0166","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0167","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-010-0146-6","article-title":"Imatinib and the treatment of fibrosis: recent trials and tribulations","volume":"13","author":"Gordon","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0168","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0169","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0170","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0171","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0172","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0173","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semarthrit.2012.06.001","article-title":"Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib","volume":"42","author":"Bournia","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.trsl.2021.01.001_bib0174","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-012-2032-2","article-title":"Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review","volume":"31","author":"Guo","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"6 Suppl 86","key":"10.1016\/j.trsl.2021.01.001_bib0175","first-page":"S189","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial","volume":"32","author":"Gordon","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0176","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0177","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jid.2018.08.021","article-title":"Notch signaling activity determines uptake and biological effect of imatinib in systemic sclerosis dermal fibroblasts","volume":"139","author":"Harrach","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0178","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard.2010.134742","article-title":"Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis","volume":"70","author":"Dees","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0179","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jaad.2010.02.030","article-title":"Imatinib treatment of generalized localized scleroderma (morphea)","volume":"63","author":"Moinzadeh","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/dth.12248","article-title":"Imatinib treatment of therapy resistant generalized deep morphea","volume":"28","author":"Alcantara-Reifs","year":"2015","journal-title":"Dermatol Ther"},{"issue":"Suppl 6","key":"10.1016\/j.trsl.2021.01.001_bib0181","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy","volume":"18","author":"Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187580","article-title":"Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Martyanov","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.01.001_bib0183","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2021.01.001_bib0184","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"Ozgur Yurttas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0185","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/14796694.4.5.611","article-title":"Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases","volume":"4","author":"Quintas-Cardama","year":"2008","journal-title":"Future Oncol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0186","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2021.01.001_bib0187","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/10428199809057558","article-title":"Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis","volume":"30","author":"Escribano","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trsl.2021.01.001_bib0188","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-019-0831-z","article-title":"Macrophages in systemic sclerosis: novel insights and therapeutic implications","volume":"21","author":"Toledo","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.trsl.2021.01.001_bib0189","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0190","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.01.001_bib0191","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0192","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 119(4)","key":"10.1016\/j.trsl.2021.01.001_bib0193","first-page":"115","article-title":"Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease","volume":"37","author":"Atanelishvili","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0194","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","article-title":"Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis","volume":"75","author":"Huang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.01.001_bib0195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2021.01.001_bib0196","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","article-title":"Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Richeldi","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0197","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0198","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.trsl.2021.01.001_bib0199","doi-asserted-by":"crossref","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.trsl.2021.01.001_bib0200","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.01.001_bib0201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.trsl.2021.01.001_bib0202","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/resp.13647","article-title":"Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: results from INPULSIS(R)-ON","volume":"25","author":"Song","year":"2020","journal-title":"Respirology"},{"issue":"Suppl 106(4)","key":"10.1016\/j.trsl.2021.01.001_bib0203","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0204","first-page":"1","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: a Japanese population analysis of the SENSCIS trial","volume":"31","author":"Kuwana","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14397595.2019.1696505","article-title":"New indication for systemic sclerosis-associated interstitial lung disease","volume":"30","author":"Kuwana","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.trsl.2021.01.001_bib0206","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:43:18Z","timestamp":1761828198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":206,"alternative-id":["S1931524421000037"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.01.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}